REFERENCES
- Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389–393.
- Cioffi GA. Ischemic model of optic nerve injury. Trans Am Ophthalmol Soc. 2005;103:592–613.
- Tezel G, Wax MB. Hypoxia-inducible factor 1 alpha in the glaucomatous retina and optic nerve head. Arch Ophthalmol. 2004;122:1348–1356.
- Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med. 2003;228:1–14.
- Bartesaghi S, Marinovich M, Corsini E, et al. Erythropoietin: A novel neuroprotective cytokine. Neurotoxicology. 2005;26:923–928.
- Katavetin P, Tungsanga K, Eiam-Ong S, et al. Antioxidative effects of erythropoietin. Kidney Int Suppl. 2007;107:10–15.
- Marti HH. Erythropoietin and the hypoxic brain. J Exp Biol. 2004;207:3233–3242.
- Hardee ME, Arcasoy MO, Blackwell KL, et al. Erythropoietin biology in cancer. Clin Cancer Res. 2006;12:332–339.
- Manzoni P, Maestri A, Gomirato G, et al. Erythropoietin as a retinal angiogenic factor. N Engl J Med. 2005;353:2190–2191.
- Inomata Y, Hirata A, Takahashi E, et al. Elevated erythropoietin in vitreous with ischemic retinal diseases. Neuroreport. 2004;15:877–879.
- Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782–792.
- Hernández C, Fonollosa A, García-Ramírez M, et al. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care. 2006;29:2028–2033.
- Jonas JB, Neumaier M. Erythropoietin levels in aqueous humour in eyes with exudative age-related macular degeneration and diabetic retinopathy. Clin Experiment Ophthalmol. 2007;35:186–187.
- Cumurcu T, Bulut Y, Demir HD, et al. Aqueous humor erythropoietin levels in patients with primary open-angle glaucoma. J Glaucoma. 2007;16:645–648.
- Fu QL, Wu W, Wang H, et al. Up-regulated endogenous erythropoietin/erythropoietin receptor system and exogenous erythropoietin rescue retinal ganglion cells after chronic ocular hypertension. Cell Mol Neurobiol. 2008;28:317–329.
- Zhong L, Bradley J, Schubert W, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci. 2007;48:1212–1218.
- Tsai JC, Wu L, Worgul B, et al. Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma. Curr Eye Res. 2005;30:1025–1031.
- Weishaupt JH, Rohde G, Pölking E, et al. Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci. 2004;45:1514–1522.
- Hodapp E, Parrish RK II, Anderson DR. Clinical Decisions in Glaucoma. St. Louis: CV Mosby Co., 1993; pp. 52–61.
- Martinez-Estrada OM, Rodriguez-Millan E, Gonzalez-De Vicente E, et al. Erythropoietin protects the in vitro blood-brain barrier against VEGF induced permeability. Eur J Neurosci. 2003;18:2538–2544.
- García-Ramírez M, Hernández C, Simó R. Expression of erythropoietin and its receptor in the human retina: A comparative study of diabetic and non-diabetic subjects. Diabetes Care. 2008;31:1189–1194.